The impact of NF-κB signaling on pathogenesis and current treatment strategies in multiple myeloma
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
30501907
DOI
10.1016/j.blre.2018.11.003
PII: S0268-960X(18)30044-4
Knihovny.cz E-zdroje
- Klíčová slova
- Bone marrow, Multiple myeloma, NF-κB, Proteasome inhibitor, Therapy,
- MeSH
- aktivace enzymů MeSH
- cílená molekulární terapie MeSH
- kostní dřeň účinky léků metabolismus patologie MeSH
- lidé MeSH
- management nemoci MeSH
- mnohočetný myelom diagnóza etiologie metabolismus terapie MeSH
- NF-kappa B antagonisté a inhibitory metabolismus MeSH
- protinádorové látky farmakologie terapeutické užití MeSH
- signální transdukce * účinky léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- NF-kappa B MeSH
- protinádorové látky MeSH
Multiple myeloma, which ranks as the second most common hematological malignancy, is known for its great genetic heterogeneity. One pathway, however, stands out in this diverse group. NF-κB pathway is one of the most important pathways in multiple myeloma not only for its role in pathogenesis, but also for its importance in various treatment strategies. Mutations in several major components of the NF-κB pathway and its regulators are present in at least 17% of primary multiple myeloma tumors and 42% of multiple myeloma cell lines. The NF-κB pathway regulates numerous genes, which influence development and pathogenesis of multiple myeloma. This significance of NF-κB for myeloma cells, however, is used against them, as current treatment strategies often use NF-κB as their primary or secondary target.
Babak Myeloma Group Department of Pathological Physiology Masaryk University Brno Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic
Citace poskytuje Crossref.org
Immunomodulatory Agents for Multiple Myeloma
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma
